InterVenn is a series b startup based in United States. 1 investor tracked.
InterVenn Biosciences is a company founded in 2017 headquartered in the United States. Brouky records 3 investors associated with the company.
InterVenn Biosciences develops an AI-driven glycoproteomics platform to identify glycoprotein biomarkers for disease detection, progression monitoring, and therapeutic response. The company provides biomarker discovery and diagnostic/monitoring solutions to clinical and research partners.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.